Sigachi Industries Ltd (SIGACHI)

Healthcare · Pharmaceuticals · NSE · Updated 13 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹37.91 ↓ 11.61% (1Y)

🎯 Key Takeaways

Sigachi Industries is in a strategic turnaround and growth phase, transitioning from historical losses to targeted profitability through capacity expansion and product innovation in its MCC segment. Management is actively investing in scale and new product adoption to drive margin improvement and accelerate revenue growth in FY27, signaling a deliberate shift from distress to structured expansion.
Revenue declined 0.5% QoQ to ₹121 in Q1FY27.
⚠️ The capital raise through convertible warrants will dilute existing shareholders and may pressure share price if not well-subscribed.

Market Cap

₹1,449

P/E Ratio

56.6

P/B Ratio

2.41

ROE

4.4%

ROCE

5.2%

Debt/Equity

0.20

Div Yield

0.26%

Promoter

36.7%

✨ Ask AI About SIGACHI 📊 Interactive Charts

📖 The Story

Sigachi Industries is in a strategic turnaround and growth phase, transitioning from historical losses to targeted profitability through capacity expansion and product innovation in its MCC segment. Management is actively investing in scale and new product adoption to drive margin improvement and accelerate revenue growth in FY27, signaling a deliberate shift from distress to structured expansion.

📰 What's Happening

In Q1 FY27, Sigachi reported revenue of INR121.27 crores and net profit of INR8.14 crores, driven by strong MCC segment performance and improved pricing realizations. Management highlighted that MCC segment revenue reached INR82.74 crores with average realization rising to INR241.36/kg. The company has scheduled an EGM on September 15, 2026 to seek shareholder approval for a capital increase and preferential issue of up to 11 million convertible warrants to raise approximately INR290.40 crores, aimed at funding expansion and working capital. This capital raise will dilute existing shareholders but is expected to increase promoter stake to 43.73% on full dilution. Additionally, the board approved raising authorized share capital to INR60 crores and appointing Care Ratings as the monitoring agency for the capital restructuring.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	128	110	117	122	121
Operating Profit	19	3	2	12	12
OPM %	15.1%	3.1%	1.3%	9.7%	10.0%
Net Profit	-101	11	-0	8	8
EPS	₹-2.63	₹0.28	₹0.01	₹0.20	₹0.18

The company has turned around from losses in prior quarters, with net profit of INR8 crores in Q1 FY27 compared to a loss of INR101 crores in Q2 FY25, indicating significant improvement in operational performance. Revenue trends show stability around INR110-122 crores in recent quarters, with operating margins expanding from 1.3% in Dec 2025 to 10% in Jun 2026, reflecting better cost control and pricing power. Management attributes this improvement to capacity utilization, product innovation like HiCel SMCC Nutra, and easing of prior constraints, supporting their target of INR650-675 crores revenue for FY27 with expanding margins.

🔮 Management Outlook & What's Next

Management has provided forward-looking guidance targeting INR650-675 crores in revenue for FY27 and expects margins to improve as capacity constraints ease and new products gain traction. They anticipate MCC capacity to reach 30,000 MT by Q2 FY28, which is central to their growth narrative. While no detailed financial targets were given beyond revenue and margin expansion, the emphasis is on scaling operations and leveraging product innovation to drive sustainable profitability. The capital raise is positioned as a strategic enabler to fund this expansion without relying on external debt at scale.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	33	38	38	38
Reserves	438	563	470	484
Borrowings	137	118	145	139
Total Liabilities	753	846	851	841
Fixed Assets	304	370	271	269
Investments	0	0	0	0
Total Assets	753	846	851	841

The balance sheet shows a stable capital structure with equity remaining flat at INR38 crores and reserves declining slightly from INR563 to INR470 crores over the past year, suggesting reserve utilization or reclassification. Borrowings have increased marginally from INR118 to INR139 crores, indicating modest leverage growth, likely tied to expansion plans. Total assets have remained stable around INR840-851 crores, reflecting capital-intensive but asset-light operational scaling. The upcoming capital raise via convertible warrants is expected to strengthen the balance sheet by funding growth without immediate debt accumulation, while improving promoter ownership.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+27
Investing	-93
Financing	+81
Net Cash Flow	+15

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	40.5%	39.7%	36.7%	36.7%
FII	3.1%	3.3%	1.3%	1.3%
DII	0.0%	0.0%	0.0%	0.0%
Public	47.5%	47.8%	54.6%	54.2%
# Shareholders	2,05,266	1,94,777	1,94,559	1,88,986

Promoter holding has declined gradually from 40.48% in Q2 FY26 to 36.69% in Q1 FY27, while FII and DII holdings remain very low (1.25% and 0% respectively), indicating limited institutional interest. However, the proposed capital increase and convertible warrant issuance are structured to increase promoter stake to 43.73% on full dilution, suggesting management intends to maintain control. The growing number of shareholders (over 1.88 lakh) reflects broad retail participation, but the lack of FII/DII accumulation may signal limited institutional confidence despite improving financials.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.42 L Cr	36.5	18.7%	14.6%	0.05
DIVISLAB	2.48 L Cr	84.6	23.0%	17.4%	0.00
TORNTPHARM	1.89 L Cr	79.4	15.1%	25.7%	1.76
ZYDUSLIFE	1.12 L Cr	24.9	16.8%	16.6%	0.43
CIPLA	1.10 L Cr	32.7	13.2%	9.8%	0.01
LAURUSLABS	1.06 L Cr	97.3	20.8%	20.6%	0.45
DRREDDY	96,906	30.0	10.1%	8.4%	0.17
AUROPHARMA	96,402	26.2	12.8%	9.8%	0.20
LUPIN	95,836	16.9	27.9%	24.7%	0.26
MANKIND	94,039	46.0	13.9%	12.7%	0.38

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. The capital raise through convertible warrants will dilute existing shareholders and may pressure share price if not well-subscribed. 2. High reliance on the MCC segment for both revenue and margin growth exposes the company to execution risks if capacity ramp-up or product adoption fails. 3. Rising borrowings alongside declining reserves warrant monitoring for leverage trends, especially if expansion does not translate into sustained profitability. 4. Low institutional ownership and thin trading volumes could lead to high volatility and limited liquidity, increasing investment risk.

📋 Recent Filings

🧠 Analyst's Read

Sigachi Industries is executing a deliberate turnaround with visible operational improvement and a clear growth strategy anchored in capacity expansion and product innovation. The success of its margin improvement and capital raise will be critical to sustaining momentum. Investors should monitor the EGM outcome, utilization of raised funds, and pace of MCC capacity ramp-up as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SIGACHI

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SIGACHI files new disclosures

Track SIGACHI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SIGACHI — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd